Mitsubishi UFJ Asset Management Co. Ltd. Raises Stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Mitsubishi UFJ Asset Management Co. Ltd. boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 7.8% during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm owned 177,008 shares of the biopharmaceutical company’s stock after purchasing an additional 12,757 shares during the quarter. Mitsubishi UFJ Asset Management Co. Ltd. owned about 0.16% of Regeneron Pharmaceuticals worth $127,118,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also made changes to their positions in the company. FSA Wealth Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter worth approximately $26,000. OFI Invest Asset Management bought a new stake in Regeneron Pharmaceuticals in the fourth quarter worth $28,000. Rakuten Securities Inc. grew its stake in shares of Regeneron Pharmaceuticals by 62.5% in the fourth quarter. Rakuten Securities Inc. now owns 39 shares of the biopharmaceutical company’s stock worth $28,000 after acquiring an additional 15 shares during the last quarter. Avalon Trust Co bought a new position in shares of Regeneron Pharmaceuticals during the fourth quarter valued at $36,000. Finally, Crowley Wealth Management Inc. purchased a new position in shares of Regeneron Pharmaceuticals in the 4th quarter worth about $36,000. Institutional investors own 83.31% of the company’s stock.

Wall Street Analyst Weigh In

REGN has been the subject of a number of analyst reports. Bernstein Bank reduced their price objective on shares of Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. Sanford C. Bernstein reduced their price target on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a research report on Tuesday, January 7th. Wells Fargo & Company lowered their price objective on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating on the stock in a research report on Friday, January 10th. Truist Financial reduced their target price on Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a “buy” rating for the company in a report on Wednesday, January 8th. Finally, Robert W. Baird lowered their price target on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating on the stock in a report on Wednesday, February 5th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $973.13.

Regeneron Pharmaceuticals Price Performance

NASDAQ REGN opened at $635.83 on Friday. The stock has a market cap of $69.51 billion, a price-to-earnings ratio of 16.61, a PEG ratio of 2.34 and a beta of 0.27. Regeneron Pharmaceuticals, Inc. has a 12 month low of $629.02 and a 12 month high of $1,211.20. The company’s 50 day moving average is $684.76 and its two-hundred day moving average is $803.87. The company has a current ratio of 4.73, a quick ratio of 3.95 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. The company had revenue of $3.79 billion for the quarter, compared to analysts’ expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. Regeneron Pharmaceuticals’s revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter in the previous year, the company earned $11.86 EPS. As a group, research analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.55%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.